Kadimastem Ltd
KDST
Clasificación en acciones
#40949
Kadimastem Ltd is a biopharmaceutical company focused on pioneering... Kadimastem Ltd is a biopharmaceutical company focused on pioneering regenerative medical treatments. These therapies are developed using cells sourced from human embryonic stem cells, primarily targeting neurodegenerative diseases. Its development pipeline features AstroRx, a clinical-grade human astrocyte product currently undergoing Phase 1/2a clinical trials for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. Additionally, the company is advancing IsletRx, a clinical-grade pancreatic islet cell therapy intended for the treatment of diabetes. Incorporated in 2008, Kadimastem is headquartered in Ness Ziona, Israel.
Precio por acción
$12.16
Última sincronización: 2025-10-30
Capitalización bursátil
$50.98K
Cambio (1 día)
-0.10%
Cambio (1 año)
69.56%
País
IL
Comercio Kadimastem Ltd (KDST)
Categoría
Healthcare
Ratio P/B de Kadimastem Ltd (KDST)
Ratio P/B al 2026 TTM: 0
Según los informes financieros más recientes y el precio de las acciones de Kadimastem Ltd, el ratio P/B actual (TTM) es 0. Al final de 2026, el ratio P/B era 0.
Historial del ratio P/B de Kadimastem Ltd desde 2026 hasta 2026
Ratio P/B al final de cada año
| Año | Ratio P/B | Cambiar |
|---|---|---|
| Not enough data for the provided dates. | ||
Ratio P/B de empresas similares o competidoras
| Empresa | Ratio P/B | Diferencia del ratio P/B | País |
|---|---|---|---|
| 6.251 | - |
US
|
|
| 13.2547 | - |
US
|
|
| 4.208 | - |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | - |
NL
|
